ObsEva (NASDAQ:OBSV) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of ObsEva (NASDAQ:OBSV) in a report issued on Wednesday morning. The brokerage issued a hold rating on the stock.

ObsEva Stock Performance

Shares of OBSV stock opened at $0.01 on Wednesday. ObsEva has a twelve month low of $0.08 and a twelve month high of $2.14. The stock has a fifty day simple moving average of $0.04 and a two-hundred day simple moving average of $0.05. The stock has a market capitalization of $623,768.00, a price-to-earnings ratio of -0.01 and a beta of 0.68.

Hedge Funds Weigh In On ObsEva

Large investors have recently bought and sold shares of the business. Two Sigma Investments LP purchased a new position in shares of ObsEva in the 3rd quarter valued at $25,000. Virtu Financial LLC purchased a new position in ObsEva in the first quarter valued at about $30,000. XTX Topco Ltd raised its holdings in ObsEva by 33.9% in the first quarter. XTX Topco Ltd now owns 79,757 shares of the company’s stock worth $120,000 after purchasing an additional 20,196 shares in the last quarter. Millennium Management LLC purchased a new stake in shares of ObsEva during the second quarter valued at about $192,000. Finally, Credit Suisse AG boosted its position in shares of ObsEva by 8.7% in the 3rd quarter. Credit Suisse AG now owns 1,577,118 shares of the company’s stock worth $224,000 after purchasing an additional 126,812 shares in the last quarter. Institutional investors own 17.52% of the company’s stock.

ObsEva Company Profile

ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women’s reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.